Loading, Please Wait...
SOUTH SAN FRANCISCO, Calif., March 28, 2019 (GLOBE NEWSWIRE) -- Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer, today announced oral and poster presentations at upcoming scientific conferences.
“We are thrilled to showcase the ongoing drug discovery efforts of our novel protein secretion program. We believe targeting the Sec61 translocon represents a unique mechanism of action that could potentially result in broad anti-tumor activity,” said Christopher Kirk, PhD, Kezar’s President and Chief Scientific Officer. “Sharing these data for the first time publicly at AACR signifies an important step towards nominating our first oncology clinical candidate later this year. Furthermore, at Lupus 2019, we will present some compelling gene expression data for KZR-616, our novel immunoproteasome inhibitor, in a murine model of lupus nephritis.”
Following is a schedule of Kezar’s upcoming scientific presentations, which will also be made available on the Company’s investor relations site:
American Association of Cancer Research (AACR), Atlanta, Georgia
Title: KZR-8834: A novel, small molecule inhibitor of Sec61-dependent protein secretion with anti-tumor activity
Date: April 2, 2019
Time: 8:00am – 12:00pm
Poster Session: PO.ET06.03 - Novel Antitumor Agents 1
Title: Discovery and characterization of novel anti-cancer small molecule inhibitors of Sec61
Date: April 2, 2019
Time: 1:00pm – 5:00pm
Poster Session: PO.ET06.04 - Novel Antitumor Agents 2
13th International Congress on Systemic Lupus Erythematosus (Lupus 2019), San Francisco, CA
Title: KZR -616, A Selective Inhibitor of the Immunoproteasome, Attenuates the Development of Murine Lupus
Date: April 6, 2019
Time: 5:20pm – 5:35pm
Oral Session: 2A: Molecular Targets
About Kezar Life Sciences
Based in South San Francisco, Kezar Life Sciences is a clinical-stage biotechnology company committed to revolutionizing treatments for patients with autoimmune diseases and cancer. Kezar is translating its innovative research on the immunoproteasome and protein secretion pathways to advance novel therapeutic approaches. KZR-616, a first-in-class immunoproteasome inhibitor, is currently in a Phase 1b trial, with a Phase 2 trial in lupus nephritis patients expected to initiate during the second quarter of 2019. Kezar is also poised to expand its development programs throughout 2019 with plans to initiate Phase 2 trials of KZR-616, in up to four additional autoimmune indications, and to nominate an initial clinical candidate for the treatment of cancer from its protein secretion program. For more information, visit www.kezarlifesciences.com.
Cautionary Note on Forward-looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “may,” “will,” “should,” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on Kezar’s expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Actual results may differ materially from these forward-looking statements. Forward-looking statements contained in this press release include, but are not limited to, (i) the discovery and development of new product candidates, and (ii) the likelihood data will support future development. Factors that may cause actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Kezar’s filings with the U.S. Securities and Exchange Commission, including the “Risk Factors” contained therein. Except as required by law, Kezar assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.
SVP, Strategy & External Affairs